LRMR
Larimar Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 157.3M | 154.2M | 73.3M | 27.7M | 24.3M |
| SG&A Expense | 21.8M | 18.3M | 17.6M | 14.1M | 12.3M |
| General & Admin Expense | 21.6M | 18.3M | 17.6M | 14.1M | 12.3M |
| Selling & Marketing Expense | 100.0K | — | — | — | — |
| Other Expenses | (100.0K) | — | — | — | — |
| Total Operating Expenses | 179.0M | 172.5M | 90.9M | 41.8M | 36.5M |
| Cost and Expenses | 179.0M | 172.5M | 90.9M | 41.8M | 36.5M |
| Operating Income (EBIT) | (179.0M) | (172.5M) | (90.9M) | (41.8M) | (36.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 6.4M | 6.8M | 10.3M | 4.8M | 1.2M |
| Non-Operating Income (excl Interest) | (6.4M) | (6.8M) | (10.3M) | (4.8M) | (1.2M) |
| EBT (Pre-Tax Income) | (172.6M) | (165.7M) | (80.6M) | (36.9M) | (35.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (172.6M) | (165.7M) | (80.6M) | (36.9M) | (35.4M) |
| Earnings from Cont. Ops | (172.6M) | (165.7M) | (80.6M) | (36.9M) | (35.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (174.1M) | (165.7M) | (80.6M) | (36.9M) | (35.4M) |
| Per Share | |||||
| Basic EPS | ($1.99) | ($2.27) | ($1.32) | ($0.84) | ($1.33) |
| Diluted EPS | ($1.99) | ($2.27) | ($1.32) | ($0.84) | ($1.33) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 103.9M | 72.9M | 61.3M | 43.9M | 25.8M |
| Diluted Shares Outstanding | 103.9M | 72.9M | 61.3M | 43.9M | 25.8M |
| Profitability Metrics | |||||
| EBITDA | (172.3M) | (165.3M) | (80.3M) | (36.6M) | (35.0M) |
| D&A | 301.0K | 350.0K | 318.0K | 311.0K | 318.0K |
| EBIT | (172.6M) | (165.7M) | (80.6M) | (36.9M) | (35.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026